NasdaqCM - Nasdaq Real Time Price USD

BriaCell Therapeutics Corp. (BCTX)

2.3200

+0.1200

(+5.45%)

At close: April 23 at 4:00 PM EDT

2.2617

-0.06

(-2.51%)

After hours: April 23 at 7:50 PM EDT

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and natural killer (NK) cellsThe novel mechanisms of action may lead to strong anti-cancer activity in breast and prostate cancer patients PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the

GlobeNewswire 13 days ago
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior treatments in Bria-IMT™ population than in comparable studies Bria-IMT™ PFS compares favorably to their most recent treatment PFS in 48% of patients Clinical benefit rate of 56% in evaluable patients71% intracranial objective response rate (iORR) in heavily pretreated patientsFindings support clinical eff

GlobeNewswire 14 days ago
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell PHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to tran

GlobeNewswire last month
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10 at San Diego Convention Center, San Diego, CA. The det

GlobeNewswire last month
BriaCell Provides Update on Alleged Illegal Trading of Public Securities

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, provides an update to the previously announced investigation of alleged illegal trading activity of its publicly traded securities. Upon external forensic analysis of data from various industry sources consistently demonstratin

GlobeNewswire last month
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapyNotable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor “no longer observed” following BriaCell treatment PHILADELPHIA and VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE

GlobeNewswire 2 months ago
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Bria-Pros+ Activates Multiple Immune Cell Types Figure 1 shows that Bria-Pros+ activates a range of immune cells in a modified mixed lymphocyte reaction. Bria-Pros+ Activates Immune Cells to Kill Cancer Cells Figure 2 shows that Bria-Pros+ cells can stimulate immune cells to kill prostate cancer cells. Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer

GlobeNewswire 2 months ago
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2023 held on January 30, 2024 (the “Meeting”). A total of 5,375,071 common shares o

GlobeNewswire 2 months ago
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

Figure 1 Magnetic resonance imaging (MRI) of the orbital tumor. The top left MRI image shows the tumor in the right orbit behind the eye with the eye not being visible pre-treatment. After treatment with the Bria-IMT™ regimen, the eye becomes visible (top right image) as it has regained its normal position. In the lower images, the dashed line represents normal margin of eye position with resolution of proptosis post treatment (small arrows) with the Bria-IMT™ regimen. Reduction in tumor is repr

GlobeNewswire 3 months ago
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint inhibitor (CPI)Tumor reductions observed in heavily pretreated patients highlight potential clinical benefit of Bria-IMT™ in managing CNS metastases PHILADELPHIA and VANCOUVER, British Columbia, Dec. 28, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“Bri

GlobeNewswire 3 months ago
$BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset$
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar studies*Progression Free Survival (PFS) was similar or better than last regimen in 40% of the patients highlighting clinical efficacyDisease control rate of 40% was observed in evaluable patients further indicating clinical benefit PHILADELPHIA and VANCOUVER, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasda

GlobeNewswire 4 months ago
BCTX: Down in San Antone

By John Vandermosten, CFA NASDAQ:BCTX San Antonio Breast Cancer Symposium Poster Presentations BriaCell Therapeutics Corp. (NASDAQ:BCTX) presented three posters at the 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting held in San Antonio, Texas. The posters addressed Bria-IMT’s successes in turning cold tumors hot, the use of imaging and protein array to evaluate immune response and

Zacks Small Cap Research 4 months ago
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*).32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit.All patients were able to receive therapy with no toxicity related discontinuations. PHILADELPHIA and VANCOUVER, British Columbia, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“Br

GlobeNewswire 4 months ago
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

BriaCell’s Bria-IMT™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning “Cold” tumors “Hot” on ImmunoPET imagingAdvanced protein array technologies showed unique antibody responses in patients with disease control who were treated with the Bria-IMT™ regimen, and may be used to predict survival and clinical benefit in cancer patientsPotent activity of the BriaCell combination regimen supports the use of the regimen in the ongoing pivotal Phase 3 s

GlobeNewswire 4 months ago
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded.Heavily treated patient had 7 prior failed regimens.The patient continues to receive treatment. PHILADELPHIA and VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology

GlobeNewswire 4 months ago
BCTX: November 2023 SITC Poster

By John Vandermosten, CFA NASDAQ:BCTX SITC Poster Presentation BriaCell Therapeutics Corp. (NASDAQ:BCTX) presented a poster at the 2023 Society for Immunotherapy of Cancer (SITC) annual meeting held in San Diego, California. It was entitled Development and Mechanism of Action of a Novel Cellular Immunotherapeutic Platform for the Treatment of Advanced Solid Tumors and addressed immune system

Zacks Small Cap Research 5 months ago
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast and prostate cancer immunotherapies Data supports further development of BriaCell’s next generation personalized immunotherapy platform with potent anti-tumor activity and favorable safety profileFDA authorizes Bria-OTS™ Investigational New Drug Application (IND) opening the path to the clinic PHILADELPHIA and VANCOUVER, British Columbia, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Thera

GlobeNewswire 5 months ago
BCTX: Year in Review

By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT Fiscal Year 2023 Operational and Financial Results On October 25th 2023, BriaCell Therapeutics Corp. (NASDAQ:BCTX) reported fiscal year 2023 financial and operational results in the filing of Form 10-K . Results were presented for the fiscal year ending July 31st, 2023. Since our previous update in early July, BriaCell has

Zacks Small Cap Research 5 months ago
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders (KOLs) Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Bruf

GlobeNewswire 5 months ago
October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology

According to American Cancer Society Facts and Figures, breast cancer is the most common cancer in the United States with 300,590 expected new cases in 202343,700 women and men are expected to die of breast cancer in the U.S. in 2023, making breast cancer the 2nd leading cause of cancer death in women in the U.S.BriaCell’s pivotal Phase 3 study (under Fast Track Designation) investigating the Bria-IMT™ regimen in advanced metastatic breast cancer is enrolling patientsBriaCell recently reported b

GlobeNewswire 6 months ago

Performance Overview

Return	BCTX	S&P/TSX Composite index
YTD	-60.34%	+5.03%
1-Year	-68.44%	+6.37%
3-Year	-21.89%	+15.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BriaCell Therapeutics Corp. (BCTX)

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

BriaCell Provides Update on Alleged Illegal Trading of Public Securities

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

BCTX: Down in San Antone

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

BCTX: November 2023 SITC Poster

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

BCTX: Year in Review

BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology

Performance Overview